In cancers other than lung cancer, ANRIL has been shown to recruit PRC2 to the CDKN2A/B locus, resulting in H3K27me3 modifications and transcriptional repression of tumor suppressor genes [140]. This evidence concerns the gene CDKN2B-AS1 and lung cancer.